sicklecellanemianews4h
Most patients free of vaso-occlusive crises for years after Casgevy dose
Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...
Hosted on MSN3d
Vertex Pharmaceuticals presents long-term data on CASGEVY at ASH
Vertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY from global clinical trials in people with severe sickle ...
Vertex reports positive long-term data for Casgevy
Vertex Pharmaceuticals (NASDAQ:VRTX) presented positive long-term data for its gene therapy Casgevy and issued a business ...
Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...
Business Wire3d
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial ...
FiercePharma1d
Vertex, Saudi Arabia ink memorandum of understanding to boost local gene therapy manufacturing
Two Saudi Arabian agencies signed on with Vertex Pharmaceuticals to help boost the countr | The Vertex agreement is part of ...
BioPharma Dive3d
Gene therapy uptake in sickle cell stays slow, despite patient interest
A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of ...
BioSpace7d
Bluebird, Vertex/CRISPR’s SCD Gene Therapies Get New CMS Payment Model
The payment scheme will tie gene therapy payments to improvements in health outcomes—and could potentially boost the uptake ...
FiercePharma8h
Lonza plans to shed capsules business, simplify operating structure in push to become 'pure-play' CDMO
With a new CEO at the helm, Swiss CDMO Lonza is looking to revivify its business by doubling down on contract manufacturing ...
Vertex, bluebird join new federal program to pay for gene therapies
Vertex Pharmaceuticals Inc. and bluebird bio Inc. — are the first to take part in a new Medicaid model intended to expand ...
3 of the Best Growth Stocks You Can Buy for Less than $100
It's getting harder these days to find great growth stocks trading for less than $100 a share. It almost seems like a higher ...
CMS enters agreement with Vertex, bluebird to improve access to gene therapies
The Centers for Medicare & Medicaid Services said on Wednesday it had entered into agreements with Vertex Pharmaceuticals and ...